Topic:

R&D

Latest Headlines

Latest Headlines

NuCana readies suite of PhIII cancer trials after rounding up mid-phase data

NuCana is set to start a Phase III trial of Acelarin in patients with pancreatic cancerthis month, kicking off a surge into late-stage studies that will see it work on ovarian and biliary programs later this year. The Sofinnova Ventures-backed biotech is initiating the multi-front advance on the strength of Phase I/II data, details of which were presented at ASCO.

Galapagos leases one-third of Sanofi-founded biopark to consolidate French R&D operations

Galapagos is moving into new digs on the outskirts of Paris. The relocation sees 130 staff move from three locations across the Biocitech campus Sanofi founded in 2002 to a newly refurbished building on the site that houses a mix of biology and chemistry laboratories.

WuXi lands a role in the U.K.'s plot to sequence 100,000 genomes

WuXi PharmaTech's NextCODE secured a spot among the companies and research institutions taking part in Genomics England, contending for a lead role in the group's ambitious effort to sequence the genomes of 100,000 people.

Building Biotech 3.0: The new rules of a changing game

The Biotech 3.0 vision is what we'll be exploring at my upcoming executive breakfast during BIO's annual conference in Philadelphia.

Quintiles cuts the ribbon on a new Chinese R&D hub

Quintiles has opened up a new, up-sized headquarters in China, toasting the country's growth as a global biopharma power and angling to play a bigger role in its continued evolution.

Calhoun Vision raises $69M for light adjustable intraocular lens FDA approval, launch

Calhoun Vision has been around a long, long time for a startup. But now it's got a massive infusion of $69 million that's following on the heels of the addition of a new, market-focused CEO from Bausch + Lomb to help catapult it into commercialization.

Active Biotech axes 84% of staff in retreat from R&D

Active Biotech has dramatically stepped up its retreat from R&D. Having dropped a pair of clinical-phase assets last year, disappointing data from a Phase III trial of tasquinimod have prompted Active Biotech to take an ax to its research operation, laying off 84% of its staff in the process.

Merck's 'landmark' Zetia data hits NEJM, giving a boost to all LDL-fighting meds

The nitty-gritty on Merck & Co.'s Zetia outcomes trial is now revealed--and it's not just good news for the cholesterol-fighting drug and its combo-pill sister Vytorin. It's good for all high-powered cholesterol meds.

Recipharm signs on to develop Follicum's hair-growth drug

Contract drug developer Recipharm has inked a deal with Swedish biotech Follicum to help get the company's top prospect into clinical trials, handling formulation and production.

Takeda to consolidate U.S. vaccines ops in Cambridge

Cambridge, MA, will get a little more crowded after Takeda's Tuesday announcement that it plans to close multiple U.S. facilities and expand its presence there into a U.S. vaccines headquarters.